<DOC>
	<DOCNO>NCT02490098</DOCNO>
	<brief_summary>Current intensive insulin therapy T1D involve prandial insulin bolus depend carbohydrate content ingest meal . Carbohydrate content ingest meal main determinant post-meal glucose excursion . Therefore , accurate carbohydrate count critical aspect manage postprandial blood glucose level type 1 diabetes order avoid much little insulin result hypoglycemia hyperglycemia , respectively . Precision carbohydrate counting associate well glycemic control . However , accurate carbohydrate count challenge task many patient type 1 diabetes . Recent development continuous glucose sensor insulin infusion pump motivate research toward `` closed-loop '' strategy regulate glucose level patient type 1 diabetes . In closed-loop strategy , pump insulin infusion rate alter base computer generate recommendation rely continuous glucose sensor reading . A dual-hormone closed-loop strategy also recently propose regulate glucose level . In dual-hormone strategy , subcutaneous insulin delivery accompany subcutaneous glucagon infusion . Postprandial meal glucose control closed-loop strategy still need improvement . The objective study test outpatient unrestricted setting whether , context closed-loop strategy , conventional meal carbohydrate counting could reduce simplified qualitative meal size estimation without significant degradation overall glycemic control child adult patient type 1 diabetes . The investigator hypothesize 1 ) dual-hormone closed-loop strategy qualitative meal size estimation equivalent dual-hormone closed-loop strategy CHO counting term mean glucose ; 2 ) single-hormone closed-loop strategy qualitative meal size estimation equivalent single-hormone closed-loop strategy CHO counting term mean glucose ;</brief_summary>
	<brief_title>Closed-loop Control Postprandial Glucose Levels Children Adults With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>1 . Males females ≥ 8 year old . 2 . Clinical diagnosis type 1 diabetes least one year . 3 . The subject insulin pump therapy least 3 month currently use fast actin insulin analog ( Lispro , Aspart Guilisine ) . 4 . Last ( less 3 month ) HbA1c ≤ 10 % . 5 . Currently use carbohydrate counting meal insulin dose strategy . 6 . Live area Montreal 1 . Clinically significant microvascular complication : nephropathy ( estimate glomerular filtration rate 40 ml/min ) , neuropathy ( especially diagnose gastroparesis ) severe proliferative retinopathy judge investigator . 2 . Recent ( &lt; 3 month ) acute macrovascular event e.g . acute coronary syndrome cardiac surgery . 3 . Pregnancy . 4 . Severe hypoglycemic episode within 1 month screening . 5 . Agents affect gastric emptying ( Motilium® , Prandase® , Victoza® , Byetta® Symlin® ) well oral antidiabetic agent ( Metformin , SGLT2 inhibitor DPP4 inhibitor ) stable dose 3 month . Otherwise , medication acceptable keep stable entire protocol . 6 . Oral steroid unless patient present low stable dose ( e.g . 10 mg less prednisone per day physiological dos , less 35 mg/day , hydrocortisone Cortef® ) . Inhale steroid stable dose last month acceptable . 7 . Other serious medical illness likely interfere study participation ability complete trial judgment investigator ( e.g . unstable psychiatric condition ) . 8 . Failure comply team 's recommendation ( e.g . willing change pump parameter , follow algorithm 's suggestion , etc ) . 9 . Living plan travel outside Montreal ( &gt; 1h drive ) area closedloop procedure .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>Closed-loop system</keyword>
	<keyword>Artificial pancreas</keyword>
	<keyword>Insulin</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Hypoglycemia</keyword>
	<keyword>Postprandial glucose</keyword>
</DOC>